MDxHealth CEO files initial ownership statement
MDxHealth SA director and Chief Executive Officer Michael McGarrity filed an initial ownership report showing his equity position in the company.
Rhea-AI Filing Summary
MDxHealth SA director and Chief Executive Officer Michael McGarrity filed an initial ownership report showing his equity position in the company. The filing lists direct holdings of 95,000 Ordinary Shares and multiple share option awards over additional Ordinary Shares.
The options cover various grants that generally vest in three equal installments over three years or upon achievement of specified company performance criteria, with exercise prices ranging from €2.90–€14.90 and $1.47–$2.62, and expiration dates between 2029 and 2035. This Form 3 is a baseline disclosure and does not report new purchases or sales.
Positive
- None.
Negative
- None.
Insider Trade Summary
13 transactions reported
Mixed
13 txns
Insider
McGarrity Michael
Role
Chief Executive Officer
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| holding | Share Option | -- | -- | -- |
| holding | Share Option | -- | -- | -- |
| holding | Share Option | -- | -- | -- |
| holding | Share Option | -- | -- | -- |
| holding | Share Option | -- | -- | -- |
| holding | Share Option | -- | -- | -- |
| holding | Share Option | -- | -- | -- |
| holding | Share Option | -- | -- | -- |
| holding | Share Option | -- | -- | -- |
| holding | Share Option | -- | -- | -- |
| holding | Share Option | -- | -- | -- |
| holding | Share Option | -- | -- | -- |
| holding | Ordinary Shares | -- | -- | -- |
Holdings After Transaction:
Share Option — 1,463,750 contracts (Direct);
Ordinary Shares — 95,000 shares (Direct)
Footnotes (12)
- F1. Represents options to purchase ordinary shares at a price per share of 14.90 Euros granted on February 18, 2019 and issued pursuant to a resolution of an extraordinary general shareholders' meeting on March 16, 2019. The options vest in three equal installments on each of the first three anniversaries of the date of grant.
- F2. Represents options to purchase ordinary shares at a price per share of 8.00 Euros granted on June 24, 2020 and issued pursuant to a resolution of an extraordinary general shareholders' meeting on July 15, 2020. The options vest in three equal installments on each of the first three anniversaries of the date of grant.
- F3. Represents options to purchase ordinary shares at a price per share of 8.00 Euros granted on June 24, 2020 and issued pursuant to a resolution of an extraordinary general shareholders' meeting on July 15, 2020. The options vested upon the achievement of certain Company performance criteria evaluated by the Board of Directors at the end of the relevant performance periods.
- F4. Represents options to purchase ordinary shares at a price per share of 13.75 Euros granted on June 23, 2021 and issued pursuant to a resolution of an extraordinary general shareholders' meeting on July 3, 2021. The options vest in three equal installments on each of the first three anniversaries of the date of grant.
- F5. Represents options to purchase ordinary shares at a price per share of 13.75 Euros granted on June 23, 2021 and issued pursuant to a resolution of an extraordinary general shareholders' meeting on July 3, 2021. The options vested upon the achievement of certain Company performance criteria evaluated by the Board of Directors at the end of the relevant performance periods.
- F6. Represents options to purchase ordinary shares at a price per share of 6.84 Euros granted on May 12, 2022 and issued pursuant to a resolution of an extraordinary general shareholders' meeting on August 3, 2022. The options vest in three equal installments on each of the first three anniversaries of the date of grant.
- F7. Represents options to purchase ordinary shares at a price per share of 6.84 Euros granted on May 12, 2022 and issued pursuant to a resolution of an extraordinary general shareholders' meeting on August 3, 2022. The options vested upon the achievement of certain Company performance criteria evaluated by the Board of Directors at the end of the relevant performance periods.
- F8. Represents options to purchase ordinary shares at a price per share of 2.90 Euros granted on March 21, 2023 and issued pursuant to a resolution of an extraordinary general shareholders' meeting on June 30, 2023. The options vest in three equal installments on each of the first three anniversaries of the date of grant.
- F9. Represents options to purchase ordinary shares at a price per share of 2.90 Euros granted on March 21, 2023 and issued pursuant to a resolution of an extraordinary general shareholders' meeting on June 30, 2023. The options vested upon the achievement of certain Company performance criteria evaluated by the Board of Directors at the end of the relevant performance periods.
- F10. Represents options to purchase ordinary shares at a price per share of $2.62 granted on February 20, 2024 and issued pursuant to a resolution of an extraordinary general shareholders' meeting on June 22, 2024. The options vest in three equal installments on each of the first three anniversaries of the date of grant.
- F11. Represents options to purchase ordinary shares at a price per share of $2.62 granted on February 20, 2024 and issued pursuant to a resolution of an extraordinary general shareholders' meeting on June 22, 2024. The options vested upon the achievement of certain Company performance criteria evaluated by the Board of Directors at the end of the performance periods.
- F12. Represents options to purchase ordinary shares at a price per share of $1.47 granted on March 26, 2025 and issued pursuant to a resolution of an extraordinary general shareholders' meeting on April 11, 2025. The options vest in three equal installments on each of the first three anniversaries of the date of grant.
Key Figures
Direct ordinary shares: 95,000 Ordinary Shares
Option grant expiring 2035: 500,000 underlying Ordinary Shares at $1.47
Option grant expiring 2034: 287,500 underlying Ordinary Shares at $2.62
+4 more
7 metrics
Direct ordinary shares
95,000 Ordinary Shares
Directly held by CEO Michael McGarrity as reported in Form 3
Option grant expiring 2035
500,000 underlying Ordinary Shares at $1.47
Share option with $1.47 exercise price expiring April 11, 2035
Option grant expiring 2034
287,500 underlying Ordinary Shares at $2.62
Share option with $2.62 exercise price expiring June 22, 2034
Euro-denominated grant 2019
€14.90 exercise price
Options granted February 18, 2019, vesting over three years
Euro-denominated grant 2020
€8.00 exercise price
Options granted June 24, 2020, time- and performance-vested
Euro-denominated grant 2023
€2.90 exercise price
Options granted March 21, 2023, time- and performance-vested
US dollar grant 2024
$2.62 exercise price
Options granted February 20, 2024, time- and performance-vested
Key Terms
extraordinary general shareholders' meeting, vesting, performance criteria, Ordinary Shares, +1 more
5 terms
vesting financial
"The options vest in three equal installments on each of the first three anniversaries of the date of grant."
Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.
performance criteria financial
"options vested upon the achievement of certain Company performance criteria evaluated by the Board of Directors"
Form 3 regulatory
"This Form 3 is a baseline disclosure and does not report new purchases or sales."
Form 3 is the initial public filing that officers, directors and large shareholders must submit to report their ownership of a company’s securities when they become insiders. It acts like an opening inventory sheet that gives investors a starting point to see who holds significant stakes and to spot later trades or potential conflicts of interest, helping assess insider confidence and transparency.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What does MDXH CEO Michael McGarrity report in this Form 3 filing?
Michael McGarrity reports his initial ownership in MDxHealth SA, including 95,000 Ordinary Shares and several share option grants over additional Ordinary Shares. These options have specified exercise prices, vesting schedules, and expiration dates, establishing a baseline view of his equity incentives.
Do the MDXH CEO’s options in this Form 3 have performance-based vesting?
Yes. Several option grants vest upon achieving company performance criteria evaluated by the Board of Directors after defined performance periods. Other grants follow time-based vesting in three equal installments on each of the first three anniversaries of their grant dates.
AI-generated analysis. How Rhea-AI works. Not financial advice.
